PDCD1 and pachyonychia congenita: In a transgenic mouse model of resectable PC, a neoadjuvant PD-1 antagonist (150 mg/mouse at day 0, 3, 6; clone RMP1–14) with gemcitabine (100 mg/kg at day 0, 3, 6) resulted in significantly improved survival compared with neoadjuvant gemcitabine alone.